Abbott Laboratories vs Core Scientific Inc — how do they compare? Abbott Laboratories trades at $109.36 (market cap $187.95B), while Core Scientific Inc trades at $20.76 (market cap $6.25B). The key difference: Abbott Laboratories is far larger — about 30.1× Core Scientific Inc's market cap, and Abbott Laboratories pays a 2.32% dividend while Core Scientific Inc pays none. Which is the better fit depends on your goals.
| ABT | CORZ | |
|---|---|---|
Market Cap | $187.95B | $6.25B |
Sector | Health | Technology |
52-Week High | $136.62 | $29.16 |
52-Week Low | $82.57 | $13.55 |
Enterprise Value | $214.96B | $8.78B |
Dividend Yield | 2.32% | — |
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $109.74, up 1.8% on the day, with a bullish technical signal from moving averages and strong analyst consensus. Recent financials show revenue growth to $44.33 billion in 2025, though net income declined to $6.52 billion. Key developments include a CE Mark for dual glucose-ketone sensors, enhancing its diabetes care portfolio. The stock is near its 52-week high, with support at $108 and resistance at $109.
Outlook remains positive with a consensus price target of $120.70, offering ~10% upside. Risks include competitive pressures in medical devices and macroeconomic volatility. Earnings beats in Q1 and Q2 2026 support growth, but margin compression and high P/E of 35.15 warrant caution for value-focused investors.
Core Scientific (CORZ) trades at $21.01, down 0.19% on the day, with technical indicators showing a bearish trend despite neutral oscillators. The company reported Q2 2026 revenue growth but missed earnings expectations with a significant net loss of -$1.4 billion for 2026. Recent news highlights a major partnership with AMD for AI infrastructure development, potentially driving future revenue growth through colocation services.
While analyst consensus remains strongly bullish with an 86% buy rating and $35.88 price target, fundamental risks include persistent negative profit margins and substantial cash burn. The AMD partnership offers significant upside potential, but investors must weigh execution risks against the company's current unprofitability and competitive pressures in the data center market.
Trailing returns across standard periods
Latest headlines on both assets
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →Core Scientific provides digital infrastructure for Bitcoin mining and high-performance computing (HPC). It operates purpose-built data centers to support digital asset production and AI-related workloads.
Read more on CORZ →